Funding Tracker/Variational AI
Pharma collaboration · Pharma & Drug Discovery · Canada
Variational AI: Pharma collaboration
Announced September 23, 2025
The round
The SignalThe official announcement is dated September 23, 2025, not November 2026. Variational AI and Merck collaborated to fine-tune Enki on Merck proprietary data for two undisclosed small-molecule targets. The agreement could be worth up to US$349 million in upfront and milestone payments; this ceiling is not disclosed funding received. Merck is the collaboration partner, not a lead investor.
What Variational AI does
Generative chemistry company developing the Enki platform for small-molecule design.
Variational AI develops Enki for small-molecule design. Its official September 23, 2025 announcement describes a collaboration with Merck using Enki fine-tuned on Merck proprietary data to design small molecules for two undisclosed targets. Potential upfront and milestone payments total up to US$349 million; this is a collaboration ceiling, not disclosed cash already received. The November 4 directory sync references this existing collaboration, not a new November 2026 deal.
Full Variational AI profile- Company
- Variational AI
- Consideration
- Undisclosed
- Stage
- Pharma collaboration
- Announced
- September 23, 2025
- Led by
- Not disclosed
- Vertical
- Pharma & Drug Discovery
- Country
- Canada